TABLE 1.

Overview of SIV vaccine challenge studies

StudyVaccineNo. of macaquesTiming (wk)Total study duration (wk)
PrimingBoosterImmunizationsChallenged
AaControl rAAV2Control rAAV250, 243863
rAAV2/SIVrAAV2/SIV5
BbControl rAAV2Control rAAV280, 121568
rAAV2/SIVrAAV2/SIV8
CcControl DNAControl DNA4DNA prime (control or SIV) given at weeks 0, 5, and 14;2881
Control rAAV24
SIV DNASIV DNA4DNA or rAAV boost per dose (control or SIV given at 24 weeks)
rAAV2/SIV4
  • a rAAV2/SIV vaccine contained a mixture of two rAAV particles, gag-PR-ΔRT and rev-gp160.

  • b rAAV2/SIV vaccine contained a mixture of three rAAV particles, gag-PR-ΔRT, RT-IN, and rev-gp160.

  • c SIV DNA vaccine was a mixture of three plasmids containing the same genes listed in footnote b.

  • d Challenge virus was SIVsm/E600 given intravenously. The dose in study A was 2 MID50. In studies B and C, the dose was 50 MID50.